SLFN11 and nonpapillary renal cell carcinoma: Although the DNA repair-related function of SLFN11 gives it a “beneficial” predictive value in patients treated with DNA-damaging drugs (such as platinum and PARP inhibitors) (14, 18, 40, 41), the first-line treatment of ccRCC mainly relies on anti-angiogenic drugs and immune checkpoint inhibitors (ICIs).